1
|
Auersperg N, Edelson MI, Mok SC, Johnson
SW and Hamilton TC: The biology of ovarian cancer. Semin Oncol.
25:281–304. 1998.
|
2
|
Auersperg N, Wong AS, Choi KC, Kang SK and
Leung PC: Ovarian surface epithelium: biology, endocrinology, and
pathology. Endocr Rev. 22:255–288. 2001.PubMed/NCBI
|
3
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Tian E and Ten Hagen KG: Recent insights
into the biological roles of mucin-type O-glycosylation. Glycoconj
J. 26:325–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ten Hagen KG, Fritz TA and Tabak LA: All
in the family: the UDP-GalNAc:polypeptide
N-acetylgalactosaminyltransferases. Glycobiology. 13:1–16.
2003.PubMed/NCBI
|
6
|
Tarp MA and Clausen H: Mucin-type
O-glycosylation and its potential use in drug and vaccine
development. Biochim Biophys Acta. 1780:546–563. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hakomori S: Glycosylation defining cancer
malignancy: new wine in an old bottle. Proc Natl Acad Sci USA.
99:10231–10233. 2002. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ,
Chen CH, Huang J, Lai HS, Lee PH, Hsu WM, Huang HC and Huang MC:
Mucin glycosylating enzyme GALNT2 regulates the malignant character
of hepatocellular carcinoma by modifying the EGF receptor. Cancer
Res. 71:7270–7279. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Taniuchi K, Cerny RL, Tanouchi A, Kohno K,
Kotani N, Honke K, Saibara T and Hollingsworth MA: Overexpression
of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell
growth. Oncogene. 30:4843–4854. 2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Park JH, Katagiri T, Chung S, Kijima K and
Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6
disrupts mammary acinar morphogenesis through O-glycosylation of
fibronectin. Neoplasia. 13:320–326. 2011.PubMed/NCBI
|
11
|
Wu C, Shan Y, Liu X, Song W, Wang J, Zou
M, Wang M and Xu D: GalNAc-T14 may be involved in regulating the
apoptotic action of IGFBP-3. J Biosci. 34:389–395. 2009. View Article : Google Scholar : PubMed/NCBI
|
12
|
Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang
B, Song W, Ma S, Ge J, Deng H and Zhu M:
N-Acetylgalactosaminyltransferase-14 as a potential biomarker for
breast cancer by immunohistochemistry. BMC Cancer. 10:123–130.
2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wagner KW, Punnoose EA, Januario T,
Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF,
Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L and
Ashkenazi A: Death-receptor O-glycosylation controls tumor-cell
sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med.
13:1070–1077. 2007. View
Article : Google Scholar : PubMed/NCBI
|
14
|
Packer LM, Williams SJ, Callaghan S,
Gotley DC and McGuckin MA: Expression of the cell surface mucin
gene family in adenocarcinomas. Int J Oncol. 25:1119–1126.
2004.PubMed/NCBI
|
15
|
Maher DM, Gupta BK, Nagata S, Jaggi M and
Chauhan SC: Mucin 13: structure, function, and potential roles in
cancer pathogenesis. Mol Cancer Res. 9:531–537. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Williams SJ, Wreschner DH, Tran M, Eyre
HJ, Sutherland GR and McGuckin MA: Muc13, a novel human cell
surface mucin expressed by epithelial and hemopoietic cells. J Biol
Chem. 276:18327–18336. 2001. View Article : Google Scholar : PubMed/NCBI
|
17
|
Shimamura T, Ito H, Shibahara J, Watanabe
A, Hippo Y, Taniguchi H, Chen Y, Kashima T, Ohtomo T, Tanioka F,
Iwanari H, Kodama T, Kazui T, Sugimura H, Fukayama M and Aburatani
H: Overexpression of MUC13 is associated with intestinal-type
gastric cancer. Cancer Sci. 96:265–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Walsh MD, Young JP, Leggett BA, Williams
SH, Jass JR and McGuckin MA: The MUC13 cell surface mucin is highly
expressed by human colorectal carcinomas. Hum Pathol. 38:883–892.
2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Chauhan SC, Ebeling MC, Maher DM, Koch MD,
Watanabe A, Aburatani H, Lio Y and Jaggi M: MUC13 mucin augments
pancreatic tumorigenesis. Mol Cancer Ther. 11:24–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Chauhan SC, Vannatta K, Ebeling MC,
Vinayek N, Watanabe A, Pandey KK, Bell MC, Koch MD, Aburatani H,
Lio Y and Jaggi M: Expression and functions of transmembrane mucin
MUC13 in ovarian cancer. Cancer Res. 69:765–774. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Wang H, Tachibana K, Zhang Y, Iwasaki H,
Kameyama A, Cheng L, Guo J, Hiruma T, Togayachi A, Kudo T, Kikuchi
N and Narimatsu H: Cloning and characterization of a novel
UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase,
pp-GalNAc-T14. Biochem Biophys Res Commun. 300:738–744. 2003.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Nagao M, Nakamura M, Oka N, Akiguchi I and
Kimura J: Abnormal glycosylation of motor neurons with
N-acetyl-D-galactosamine in a case of subacute motor neuronopathy
associated with lymphoma. J Neurol. 241:372–375. 1994. View Article : Google Scholar : PubMed/NCBI
|
23
|
Park JH, Nishidate T, Kijima K, Ohashi T,
Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T:
Critical roles of mucin 1 glycosylation by transactivated
polypeptide N-acetylgalactosaminyltransferase 6 in mammary
carcinogenesis. Cancer Res. 70:2759–2769. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Singh RK, Gutman M, Radinsky R, Bucana CD
and Fidler IJ: Expression of interleukin 8 correlates with the
metastatic potential of human melanoma cells in nude mice. Cancer
Res. 54:3242–3247. 1994.PubMed/NCBI
|
25
|
Luca M, Huang S, Gershenwald JE, Singh RK,
Reich R and Bar-Eli M: Expression of interleukin-8 by human
melanoma cells up-regulates MMP-2 activity and increases tumor
growth and metastasis. Am J Pathol. 151:1105–1113. 1997.PubMed/NCBI
|
26
|
De Larco JE, Wuertz BR, Rosner KA,
Erickson SA, Gamache DE, Manivel JC and Furcht LT: A potential role
for interleukin-8 in the metastatic phenotype of breast carcinoma
cells. Am J Pathol. 158:639–646. 2001.PubMed/NCBI
|
27
|
Groux-Degroote S, Krzewinski-Recchi MA,
Cazet A, Vincent A, Lehoux S, Lafitte JJ, Van Seuningen I and
Delannoy P: IL-6 and IL-8 increase the expression of
glycosyltransferases and sulfotransferases involved in the
biosynthesis of sialylated and/or sulfated Lewisx
epitopes in the human bronchial mucosa. Biochem J. 410:213–223.
2008. View Article : Google Scholar : PubMed/NCBI
|
28
|
Freire-de-Lima L, Gelfenbeyn K, Ding Y,
Mandel U, Clausen H, Handa K and Hakomori SI: Involvement of
O-glycosylation defining oncofetal fibronectin in
epithelial-mesenchymal transition process. Proc Natl Acad Sci USA.
108:17690–17695. 2011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Seales EC, Shaikh FM, Woodard-Grice AV,
Aggarwal P, McBrayer AC, Hennessy KM and Bellis SL: A protein
kinase C/Ras/ERK signaling pathway activates myeloid fibronectin
receptors by altering beta1 integrin sialylation. J Biol Chem.
280:37610–37615. 2005. View Article : Google Scholar : PubMed/NCBI
|
30
|
Carraway KL III, Funes M, Workman HC and
Sweeney C: Contribution of membrane mucins to tumor progression
through modulation of cellular growth signaling pathways. Curr Top
Dev Biol. 78:1–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
31
|
Schjoldager KT, Vester-Christensen MB,
Bennett EP, Levery SB, Schwientek T, Yin W, Blixt O and Clausen H:
O-glycosylation modulates proprotein convertase activation of
angiopoietin-like protein 3: possible role of polypeptide
GalNAc-transferase-2 in regulation of concentrations of plasma
lipids. J Biol Chem. 285:36293–36303. 2010. View Article : Google Scholar
|
32
|
Zhang L, Tran DT and Ten Hagen KG: An
O-glycosyltransferase promotes cell adhesion during development by
influencing secretion of an extracellular matrix integrin ligand. J
Biol Chem. 285:19491–19501. 2010. View Article : Google Scholar : PubMed/NCBI
|
33
|
Baldus SE, Engelmann K and Hanisch FG:
MUC1 and the MUCs: a family of human mucins with impact in cancer
biology. Crit Rev Clin Lab Sci. 41:189–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
34
|
Springer GF, Desai PR, Ghazizadeh M and
Tegtmeyer H: T/Tn pancarcinoma autoantigens: fundamental,
diagnostic, and prognostic aspects. Cancer Detect Prev. 19:173–182.
1995.PubMed/NCBI
|
35
|
Springer GF: Immunoreactive T and Tn
epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol
Med. 75:594–602. 1997. View Article : Google Scholar : PubMed/NCBI
|
36
|
Li Q, Anver MR, Butcher DO and
Gildersleeve JC: Resolving conflicting data on expression of the Tn
antigen and implications for clinical trials with cancer vaccines.
Mol Cancer Ther. 8:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
37
|
Babino A, Oppezzo P, Bianco S, Barrios E,
Berois N, Navarrete H and Osinaga E: Tn antigen is a pre-cancerous
biomarker in breast tissue and serum in n-nitrosomethylurea-induced
rat mammary carcinogenesis. Int J Cancer. 86:753–759. 2000.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Ando H, Matsushita T, Wakitani M, Sato T,
Kodama-Nishida S, Shibata K, Shitara K and Ohta S: Mouse-human
chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat
cells in vitro and in vivo. Biol Pharm Bull. 31:1739–1744. 2008.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Takahashi HK, Metoki R and Hakomori S:
Immunoglobulin G3 monoclonal antibody directed to Tn antigen
(tumor-associated alpha-N-acetylgalactosaminyl epitope) that does
not cross-react with blood group A antigen. Cancer Res.
48:4361–4367. 1988.
|
40
|
Zhang M, Yao Z, Saga T, Sakahara H,
Nakamoto Y, Sato N, Nakada H, Yamashina I and Konishi J: Improved
intratumoral penetration of radiolabeled streptavidin in
intraperitoneal tumors pretargeted with biotinylated antibody. J
Nucl Med. 39:30–33. 1998.
|
41
|
Elhammer AP, Poorman RA, Brown E, Maggiora
LL, Hoogerheide JG and Kézdy FJ: The specificity of UDP-GalNAc:
polypeptide N-acetylgalactosaminyltransferase as inferred from a
database of in vivo substrates and from the in vitro glycosylation
of proteins and peptides. J Biol Chem. 268:10029–10038. 1993.
|